M. H. T. Bhatti, Sarim Sohail, M. U. Aslam, Hana Ather, T. Hussain, Muhammad Kashif
{"title":"Formulation, development and characterization of ibuprofen microemulgel for arthritis","authors":"M. H. T. Bhatti, Sarim Sohail, M. U. Aslam, Hana Ather, T. Hussain, Muhammad Kashif","doi":"10.56770/jcp2022623","DOIUrl":null,"url":null,"abstract":"Objective: Microemulgel is composed of aqueous phase, lipophilic phase, along with surfactant and co-surfactant, a suitable gelling agent is also incorporated. The drug Ibuprofen is non-steroidal anti-inflammatory drug. Its oral administration associated with many GIT, hepatic and renal problems. The main objective of the study was to formulate a stable topical microemulgel of ibuprofen in order to achieve the highest bioavailability with least side effects. Method: Pseudo ternary phase diagram was constructed in order to get the suitable concentrations of lipophilic phase, surfactant and co-surfactant. Phase titration method was used to prepare microemulsion, with surfactant and co-surfactant in a ratio of 2:1 respectively, along with gelling agent to form microemulgel. Formulations were evaluated to check appearance, pH, flowability, particle size, drug content, spreadability, drug release and skin irritation. Results: The globule size of microemulsion was 400 nm and zeta potential was -14 mV showing acceptable stability. Formulated emulgel showed good physical characteristics, suitable pH of 6.4 for skin. The drug content was 98.474%. The stability study showed that the ibuprofen was stable in phosphate buffer pH of 6.8. The carbopol 940 as a gelling agent showed high release rate values. The release rate of the optimized formulation, F1 was 94% and it followed Korsmeyer Peppas model (n=0.467). Conclusion: The prepared formulation was cost-effective because of promising highest bioavailability. The results suggest the potential use of developed microemulgel is mainly for topical delivery of ibuprofen, ensuring the safe use.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":"106 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56770/jcp2022623","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Microemulgel is composed of aqueous phase, lipophilic phase, along with surfactant and co-surfactant, a suitable gelling agent is also incorporated. The drug Ibuprofen is non-steroidal anti-inflammatory drug. Its oral administration associated with many GIT, hepatic and renal problems. The main objective of the study was to formulate a stable topical microemulgel of ibuprofen in order to achieve the highest bioavailability with least side effects. Method: Pseudo ternary phase diagram was constructed in order to get the suitable concentrations of lipophilic phase, surfactant and co-surfactant. Phase titration method was used to prepare microemulsion, with surfactant and co-surfactant in a ratio of 2:1 respectively, along with gelling agent to form microemulgel. Formulations were evaluated to check appearance, pH, flowability, particle size, drug content, spreadability, drug release and skin irritation. Results: The globule size of microemulsion was 400 nm and zeta potential was -14 mV showing acceptable stability. Formulated emulgel showed good physical characteristics, suitable pH of 6.4 for skin. The drug content was 98.474%. The stability study showed that the ibuprofen was stable in phosphate buffer pH of 6.8. The carbopol 940 as a gelling agent showed high release rate values. The release rate of the optimized formulation, F1 was 94% and it followed Korsmeyer Peppas model (n=0.467). Conclusion: The prepared formulation was cost-effective because of promising highest bioavailability. The results suggest the potential use of developed microemulgel is mainly for topical delivery of ibuprofen, ensuring the safe use.